← Back to patent-cliff list
Tezacaftor/Ivacaftor
Tier B — Position earlyTezacaftor/Ivacaftor
Vertex Pharmaceuticals Incorporated
Originator
2018
First approval
-
Expiry (public)
$1.42B ▲
Peak sales
化学药
Type
Targets：CFTR、PGY1
Brand：PrSYMDEKO、Symdeko、Symkevi
Indications (approved)：囊性纤维化
Regional status
US
批准上市
2018-02-12
EU
批准上市
2018-10-31
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Tezacaftor/Ivacaftor?
Approved indications include: 囊性纤维化.
When does the Tezacaftor/Ivacaftor patent expire?
No public expiry year is available for Tezacaftor/Ivacaftor yet; this page updates once verified.
How do I get a quote for Tezacaftor/Ivacaftor intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24